Omeros

so what does this mean?

 

See you guys at 6! This stock is trash.

 

Omidria® (phenylephrine and ketorolac injection) 1% / 0.3% will be the focus of a series of presentations and panel discussions by thought leaders in cataract surgery at Hawaiian Eye and Retina, an annual conference of over 1,200 ophthalmologists, retina specialists, nurses, allied health professionals and administrators. The first of these presentations and discussions will occur on Sunday, January 17, 2016, at which time certain information regarding Omidria will be made public. To ensure that developments regarding Omeros’ business are publicly disseminated to securities markets in consistent fashion, Omeros is announcing that the information to be presented at the conference includes a summary of investigator-sponsored studies, which have resulted in abstracts and manuscripts accepted, submitted or in preparation, reporting that the use of Omidria across a wide range of patients, including those with non-complex cataracts, complex cataracts, intraoperative floppy iris syndrome (IFIS) and/or pseudoexfoliation, has resulted in statistically significant:

• reduction in complications associated with small pupils;
• reduction in usage of pupil-expanding devices;
• prevention of miosis during femtosecond laser-assisted surgery;
• reduction in age-adjusted surgical times; and
• improvement in best corrected visual acuity (BCVA) on the day after surgery.

The above outcomes are not referenced in the currently approved labeling for Omidria. Omidria is broadly indicated for use in cataract surgery in adult patients.

The above findings are from investigator-sponsored, case-controlled/cohort, single-center studies, ranging from approximately 50 to over 1,100 patients, and have not yet been published. Omeros’ earlier Phase 3 clinical trials evaluating Omidria were not powered to demonstrate statistical differences in surgical times and BCVA, and results from those Phase 3 trials did not reach statistical significance for those measurements. Complication rates and use of pupil-expanding devices were not assessed in the Phase 3 trials, and femtosecond laser cases were excluded for purposes of standardization given that not all investigators in the Omidria Phase 3 program used this equipment in cataract surgery. Consistent with publication guidelines, detailed data from these investigator-sponsored studies will be available in the published abstracts and journal articles.

 

Is it true we are giving out more free drug than what we are selling?

 

I am glad i did not accept the position at this company, i knew it was a stupid drug

 

Super Bowl Sunday should be fun!

 

The company has given away more drug than it has sold. Why pay almost 500 dollars for two old generic drugs that can be compounded for 5 bucks? Great job of ripping medicare off Omeros.

 

this place is a shit hole editing to implode

 

Hey Sales Reps! You better start cracking the whip!

Webcast Wednesday 4/13 ....... post webcast comment
I had been assuming (perhaps erroneously?) that the Omidria program within OMER was projected to become cash flow positive later this year. However, at the end of the brief Q&A today, Demopulos stated explicitly that the Omidria program is already cash flow positive and that they expect Omidria to make OMER,the full company, cash flow positive later this year.

Thumbs up!

 

Oh ouch! I don't think I like it around here anymore.

 

How is sales/marketing mgt/leadership still around with these consistent poor results Q after Q??

 

This place sucks! Ready to implode.

 

God Bless Greg for all of his "optimism" on continued pass through status for Omidria. What a fool!

 

No kidding! He'll wait until sales are literally zero to sell stock and finance the company for the next 12 months...

 

Greg, what the FUCK are you doing in the C-suite? You single-handedly took the stock from $27 to $9 because of your BS press releases!!! Any sensible, ethical person would just put the bad news out and move on and pivot to the pipeline. But NO! You choose to pretend like Omidria hasn't gone to zero overnight, continue to put out BS releases on 721, and act like there isn't an elephant in the room!

Well guess what Greggy Boy? The elephant has its giant foot on your neck! How bout them debt covenants, dipshit?!?! Haha!!!

 

I noticed multiple postings for open sales rep positions. How is the company doing? I see that it is a small company and it looks like there are reimbursement issues. It looks like that should be taken care of soon and customers will get paid.

Is that the case? Any other insights would be appreciated.

Thanks

 

A recruiter contacted me and was totally pathetic and reflected very badly on the company.

 

Me too! What was your experience?